Johnson & Johnson EBITDA 2012-2026 | JNJ
Johnson & Johnson annual and quarterly EBITDA history from 2012 to 2026. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Johnson & Johnson EBITDA for the quarter ending June 30, 2026 was $9.206B, a 2.27% increase year-over-year.
- Johnson & Johnson EBITDA for the twelve months ending June 30, 2026 was $34.871B, a 5.27% decline year-over-year.
- Johnson & Johnson 2025 annual EBITDA was $42.111B, a 61.26% increase from 2024.
- Johnson & Johnson 2024 annual EBITDA was $26.113B, a 6.23% increase from 2023.
- Johnson & Johnson 2023 annual EBITDA was $24.581B, a 9.28% decline from 2022.
|
Johnson & Johnson Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $42,111 |
| 2024 | $26,113 |
| 2023 | $24,581 |
| 2022 | $27,095 |
| 2021 | $26,804 |
| 2020 | $24,040 |
| 2019 | $25,012 |
| 2018 | $26,544 |
| 2017 | $24,634 |
| 2016 | $24,651 |
| 2015 | $23,622 |
| 2014 | $25,058 |
| 2013 | $20,131 |
| 2012 | $18,037 |
| 2011 | $16,181 |
|
Johnson & Johnson Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $9,206 |
| 2026-03-31 | $8,495 |
| 2025-12-31 | $7,428 |
| 2025-09-30 | $9,742 |
| 2025-06-30 | $9,002 |
| 2025-03-31 | $15,939 |
| 2024-12-31 | $6,201 |
| 2024-09-30 | $5,669 |
| 2024-06-30 | $8,195 |
| 2024-03-31 | $6,048 |
| 2023-12-31 | $7,183 |
| 2023-09-30 | $7,612 |
| 2023-06-30 | $8,783 |
| 2023-03-31 | $1,003 |
| 2022-12-31 | $4,688 |
| 2022-09-30 | $7,058 |
| 2022-06-30 | $7,686 |
| 2022-03-31 | $7,663 |
| 2021-12-31 | $3,154 |
| 2021-09-30 | $5,696 |
| 2021-06-30 | $8,553 |
| 2021-03-31 | $9,401 |
| 2020-12-31 | $3,687 |
| 2020-09-30 | $6,275 |
| 2020-06-30 | $5,730 |
| 2020-03-31 | $8,348 |
| 2019-12-31 | $6,200 |
| 2019-09-30 | $3,511 |
| 2019-06-30 | $8,917 |
| 2019-03-31 | $6,384 |
| 2018-12-31 | $5,303 |
| 2018-09-30 | $6,572 |
| 2018-06-30 | $7,069 |
| 2018-03-31 | $7,600 |
| 2017-12-31 | $4,788 |
| 2017-09-30 | $6,804 |
| 2017-06-30 | $6,230 |
| 2017-03-31 | $6,812 |
| 2016-12-31 | $5,663 |
| 2016-09-30 | $6,478 |
| 2016-06-30 | $6,082 |
| 2016-03-31 | $6,428 |
| 2015-12-31 | $5,004 |
| 2015-09-30 | $5,206 |
| 2015-06-30 | $6,785 |
| 2015-03-31 | $6,627 |
| 2014-12-31 | $3,850 |
| 2014-09-30 | $7,897 |
| 2014-06-30 | $6,720 |
| 2014-03-31 | $6,591 |
| 2013-12-31 | $4,004 |
| 2013-09-30 | $4,766 |
| 2013-06-30 | $5,918 |
| 2013-03-31 | $5,443 |
| 2012-12-31 | $4,261 |
| 2012-09-30 | $4,750 |
| 2012-06-30 | $3,044 |
| 2012-03-31 | $5,982 |
| 2011-12-31 | $1,379 |
| 2011-09-30 | $5,045 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $641.804B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Sanofi (SNY) | France | $105.050B | 8.84 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |